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doi:10.1016/j.tcmj.2012.04.002Type 2 mucopolysaccharidosis (MPS), also calledHunter
syndrome (MIM:309900), is a rare X-linked genetic disorder caused
by mutation in the iduronate 2-sulfatase gene (IDS: 300823). The
gene encodes for the lysosomal enzyme iduronate 2-sulfatase (I2S),
which is responsible for degradation of the glycosaminoglycans
(GAGs) heparin sulphate (HS) and dermatan sulphate (DS).
Consequent accumulation of GAGs leads to pathologic changes in
multiple organ systems.
Clinically, patients often present with dysmorphic facial features
(Fig. 1), skeletal deformities, joint stiffness, and short stature. Other
clinical manifestations include valvular heart disease and hyper-
trophic cardiomyopathy, obstructive sleep apnea due to airway
obstruction, and variable neurologic deﬁcits such as mild to
profound mental retardation. Diagnosis of MPS includes analysis of
urine GAGs, enzyme assay from leukocytes or culture ﬁbroblasts,
and gene analysis of the IDS gene. Before the era of enzyme
replacement therapy (ERT), patients usually died during the second
decade of life due to cardiopulmonary failure.
ERT with recombinant I2S [idursulfase (Elaprase, Shire Human
Genetic Therapies, Inc, Lexington, MA, USA)] has been used in
patients with type 2 MPS since 2006. Its chief value is in improving
patient quality of life, with an increased 6-minute walking distance
and improved range of motion of joints. ERT has also been found to
decrease urinary GAG secretion and reduce disease severity with
less hepatosplenomegaly and improved pulmonary function, such
as in the predicted force vital capacity. The disadvantages of ERT
include the inconvenience of weekly infusions of the enzyme.
Infusion-related reactions include headache, pruritus, and urticaria,Fig. 1. Boy, 8 years of age with type 2 mucopolysaccharidosis who presented with
macrocephaly, coarse hair, a short neck, a coarse, hairy face, puffy eyelids, depressed
nasal bridge, upturned nose, macroglossia, full lips, and thick skin texture. (Used with
parental permission for academic publication).
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Fig. 2. Future perspectives for further treatment modalities for type 2 mucopoly-
saccharidosis. DS ¼ dermatan sulphate; ERT ¼ enzyme replacement therapy;
GAG ¼ glycosaminoglycans; HS ¼ heparin sulphate; I2S ¼ iduronate 2- sulfatase;
IDS ¼ iduronate 2- sulfatase gene ([ accumulation of GAG,  ¼ broken IDS);
SOT ¼ substrate optimization therapy.
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ERT is also an issue. Worldwide, there are around 720 known
patients with type 2 MPS, 15% of which are now receiving ERT. The
yearly cost for the enzyme is already around $62 million. In Taiwan,
there are now 16 patients with type 2 MPS and normal cognitive
function who are receiving ERT; the annual cost for the enzyme is
around $9 million. Most importantly, ERT is not effective incentral
nervous system involvement.
For future perspectives, an effective way to deliver enzyme
across the bloodebrain barrier is crucial for clinical studies.
Noninvasive gene targeting to the central nervous system is still in
the early stage of development. Additionally, controlled clinical
trials of hematopoietic stem cell transplantation, substratereduction therapy (such as miglustat), substrate optimization
therapy, and selective inhibitors of GAG biosynthesis (Fig. 2), and
more studies on a created IDS-knockout mouse model are needed.
To identify individuals who might beneﬁt from early treatment,
a program of newborn screening for patients with type 2 MPS is
now being developed.
ERT alone is not a cure for type 2 MPS; its long-term safety and
efﬁcacy also need to be determined through programs of the
International Hunter Outcome Survey. Managing the burden of
residual disease such as heart and skeletal complications should be
addressed. A combination of different treatment modalities may
contribute to a better treatment outcome in the future.Further reading
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